AstraZeneca has announced a £300 million investment in UK drug development, reversing a previous decision to pause investment in Cambridge, which is expected to boost local employment and enhance patient access to clinical trials, amid changes in pharmaceutical pricing agreements between the UK and US. #PharmaceuticalIndustry #Investment #LifeSciences #UK #US
What does AstraZeneca's £300m pledge for UK mean for Cambridge?
